Bio-pharmaceutical company ANI Pharmaceuticals Inc (ANI) (Nasdaq: ANIP) revealed on Monday that the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral Solution, USP 20mg/5mL has received U.S. Food and Drug Administration (FDA) approval,
The company said that Fluoxetine Oral Solution is the generic version of the Reference Listed Drug (RLD) Prozac.
According to healthcare data and analytics provider IQVIA/IMS Health, the current annual US market for Fluoxetine Oral Solution is approximately USD14.6m, ANI stated.
ANI develops, manufactures and markets high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical needs.
Mikart adds Fette double-sided tablet presses
Biocon Biologics enters five-year partnership with Sandoz Australia
Mallinckrodt names new directors
Rottendorf Pharma enhances operations with Rockwell Automation's FactoryTalk PharmaSuite MES
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition